Genetic Diagnosis Impacts Medical Management for Pediatric Epilepsies

Overview

Journal Pediatr Neurol

Specialties Neurology
Pediatrics

Date 2022 Nov 20

PMID 36403551

Authors

Isabel Haviland

Carolyn I Daniels

Caitlin A Greene

Jacqueline Drew

Jamie A Love-Nichols

Lindsay C Swanson

Lacey Smith

Duyu A Nie

Timothy Benke

Beth R Sheidley

Bo Zhang

Annapurna Poduri

Heather E Olson

Affiliations

Soon will be listed here.

Abstract

Background: Evidence of the impact of genetic diagnosis on medical management in individuals with previously unexplained epilepsy is lacking in the literature. Our goal was to determine the impact of genetic diagnosis on medical management in a cohort of individuals with early-onset epilepsy.

Methods: We performed detailed phenotyping of individuals with epilepsy who underwent clinical genetic testing with an epilepsy panel and/or exome sequencing at Boston Children's Hospital between 2012 and 2019. We assessed the impact of genetic diagnosis on medical management.

Results: We identified a genetic etiology in 152 of 602 (25%) individuals with infantile- or childhood-onset epilepsy who underwent next-generation sequencing. Diagnosis impacted medical management in at least one category for 72% of patients (110 of 152) and in more than one category in 34%. Treatment was impacted in 45% of individuals, including 36% with impact on antiseizure medication choice, 7% on use of disease-specific vitamin or metabolic treatments, 3% on pathway-driven off-label use of medications, and 10% on discussion of gene-specific clinical trials. Care coordination was impacted in 48% of individuals. Counseling on a change in prognosis was reported in 28% of individuals, and 1% of individuals had a correction of diagnosis. Impact was documented in 13 of 13 individuals with neurotypical development and in 55% of those with epilepsy onset after age two years.

Conclusion: We demonstrated meaningful impact of genetic diagnosis on medical care and prognosis in over 70% of individuals, including those with neurotypical development and age of epilepsy onset after age two years.

Citing Articles

Association of Social Determinants of Health With Genetic Test Request and Completion Rates in Children With Neurologic Disorders.

Cole J, Williams J, Sellitto A, Baratta L, Huecker J, Baldridge D Neurology. 2025; 104(5):e210275.

PMID: 39937999 PMC: 11837850. DOI: 10.1212/WNL.0000000000210275.

Genetic Testing in Epilepsy: Improving Outcomes and Informing Gaps in Research.

Habela C, Schatz K, Kelley S Epilepsy Curr. 2024; :15357597241232881.

PMID: 39554273 PMC: 11562134. DOI: 10.1177/15357597241232881.

Understanding Gratification Disorder in Childhood: A Comprehensive Review of Diagnosis, Differential Diagnosis, and Management Approaches.

Longkumer I, Patil R, Ahmed A Cureus. 2024; 16(9):e70415.

PMID: 39473641 PMC: 11519580. DOI: 10.7759/cureus.70415.

The long odyssey for the DEE-CDKL5 diagnosis: A call for action.

Valente K, Melo F, Marin R, Vega G, Neves-Borg A, Spagnol B Epilepsia Open. 2024; 9(6):2164-2172.

PMID: 39248178 PMC: 11633692. DOI: 10.1002/epi4.13031.

Genetic Diagnostic Yield in Autism Spectrum Disorder (ASD) and Epilepsy Phenotypes in Children with Genetically Defined ASD.

Lob K, Sawka D, Gaitanis J, Liu J, Nie D J Autism Dev Disord. 2024; .

PMID: 39136901 DOI: 10.1007/s10803-024-06512-1.

References

Allen A, Cossette P, Delanty N, Eichler E, Goldstein D, Han Y . De novo mutations in epileptic encephalopathies. Nature. 2013; 501(7466):217-21. PMC: 3773011. DOI: 10.1038/nature12439. View

Guerrini R, Striano P, Catarino C, Sisodiya S . Neuroimaging and neuropathology of Dravet syndrome. Epilepsia. 2011; 52 Suppl 2:30-4. DOI: 10.1111/j.1528-1167.2011.02998.x. View

Pisano T, Numis A, Heavin S, Weckhuysen S, Angriman M, Suls A . Early and effective treatment of KCNQ2 encephalopathy. Epilepsia. 2015; 56(5):685-91. DOI: 10.1111/epi.12984. View

Zhang Y, Kong W, Gao Y, Liu X, Gao K, Xie H . Gene Mutation Analysis in 253 Chinese Children with Unexplained Epilepsy and Intellectual/Developmental Disabilities. PLoS One. 2015; 10(11):e0141782. PMC: 4636363. DOI: 10.1371/journal.pone.0141782. View

Eltze C, Chong W, Cox T, Whitney A, Cortina-Borja M, Chin R . A population-based study of newly diagnosed epilepsy in infants. Epilepsia. 2012; 54(3):437-45. DOI: 10.1111/epi.12046. View

Sanchez Fernandez I, Loddenkemper T, Gainza-Lein M, Sheidley B, Poduri A . Diagnostic yield of genetic tests in epilepsy: A meta-analysis and cost-effectiveness study. Neurology. 2019; 92(5):e418-e428. PMC: 6369901. DOI: 10.1212/WNL.0000000000006850. View

Knupp K, Wirrell E . Treatment Strategies for Dravet Syndrome. CNS Drugs. 2018; 32(4):335-350. DOI: 10.1007/s40263-018-0511-y. View

. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol. 2017; 16(2):135-143. DOI: 10.1016/S1474-4422(16)30359-3. View

Rochtus A, Trowbridge S, Goldstein R, Sheidley B, Prabhu S, Haynes R . Mutations in and in a patient with early-onset epileptic encephalopathy and respiratory depression. Cold Spring Harb Mol Case Stud. 2019; 5(1). PMC: 6371743. DOI: 10.1101/mcs.a003442. View

10.

Rockowitz S, LeCompte N, Carmack M, Quitadamo A, Wang L, Park M . Children's rare disease cohorts: an integrative research and clinical genomics initiative. NPJ Genom Med. 2020; 5:29. PMC: 7338382. DOI: 10.1038/s41525-020-0137-0. View

11.

Sakki H, Dale N, Sargent J, Perez-Roche T, Bowman R . Is there consensus in defining childhood cerebral visual impairment? A systematic review of terminology and definitions. Br J Ophthalmol. 2017; 102(4):424-432. DOI: 10.1136/bjophthalmol-2017-310694. View

12.

Trump N, McTague A, Brittain H, Papandreou A, Meyer E, Ngoh A . Improving diagnosis and broadening the phenotypes in early-onset seizure and severe developmental delay disorders through gene panel analysis. J Med Genet. 2016; 53(5):310-7. PMC: 4862068. DOI: 10.1136/jmedgenet-2015-103263. View

13.

Srivastava S, Love-Nichols J, Dies K, Ledbetter D, Martin C, Chung W . Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019; 21(11):2413-2421. PMC: 6831729. DOI: 10.1038/s41436-019-0554-6. View

14.

Wang J, Gotway G, Pascual J, Park J . Diagnostic yield of clinical next-generation sequencing panels for epilepsy. JAMA Neurol. 2014; 71(5):650-1. DOI: 10.1001/jamaneurol.2014.405. View

15.

Axeen E, Olson H . Neonatal epilepsy genetics. Semin Fetal Neonatal Med. 2018; 23(3):197-203. DOI: 10.1016/j.siny.2018.01.003. View

16.

Wolff M, Johannesen K, Hedrich U, Masnada S, Rubboli G, Gardella E . Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders. Brain. 2017; 140(5):1316-1336. DOI: 10.1093/brain/awx054. View

17.

Specchio N, Curatolo P . Developmental and epileptic encephalopathies: what we do and do not know. Brain. 2020; 144(1):32-43. DOI: 10.1093/brain/awaa371. View

18.

Matias M, Wusik K, Neilson D, Zhang X, Valencia C, Collins K . Comparison of medical management and genetic counseling options pre- and post-whole exome sequencing for patients with positive and negative results. J Genet Couns. 2019; 28(2):182-193. DOI: 10.1002/jgc4.1054. View

19.

Millichap J, Park K, Tsuchida T, Ben-Zeev B, Carmant L, Flamini R . KCNQ2 encephalopathy: Features, mutational hot spots, and ezogabine treatment of 11 patients. Neurol Genet. 2016; 2(5):e96. PMC: 4995058. DOI: 10.1212/NXG.0000000000000096. View

20.

Trinka E, Cock H, Hesdorffer D, Rossetti A, Scheffer I, Shinnar S . A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015; 56(10):1515-23. DOI: 10.1111/epi.13121. View